Antifungal activity and mechanism of Citral (cas 5392-40-5), limonene and eugenol against Zygosaccharomyces rouxii
-
Add time:07/16/2019 Source:sciencedirect.com
The aim of this study was to investigate the antifungal activity and mechanisms of citral, limonene and eugenol against Zygosaccharomyces rouxii. All the three essential oil ingredients presented strong antifungal activities against Z. rouxii. Minimum inhibitory concentrations of citral, limonene and eugenol were 0.188, 0.75 and 0.4 μL/mL, and the minimum fungicidal concentrations were 0.375, 3 and 0.8 μL/mL, respectively. Scanning electron microscopy showed that the tested essential oil compounds had destructive effects on the yeast cell surface. After treated by citral, limonene and eugenol, the relative electric conductivity and leakage of nucleic acid were increased significantly. SDS-PAGE analysis indicated that the essential oil components could result in the loss of soluble proteins and might also destroy the yeast protein or inhibit their expression. These results demonstrated that citral, limonene and eugenol exerted their antifungal action against Z. rouxii through cell membrane damage and destruction of cellular proteins. This study provided a theoretical possibility that citral, limonene and eugenol could be used as natural food preservatives for the control of Z. rouxii-related spoilage in the fruit juice industry.
We also recommend Trading Suppliers and Manufacturers of Citral (cas 5392-40-5). Pls Click Website Link as below: cas 5392-40-5 suppliers
Prev:Effect of drying and interfacial membrane composition on the antimicrobial activity of emulsified Citral (cas 5392-40-5)
Next:Physiological response of Saccharomyces cerevisiae to Citral (cas 5392-40-5) combined with thermal treatment) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Vasorelaxant effect of the Lippia alba essential oil and its major constituent, Citral (cas 5392-40-5), on the contractility of isolated rat aorta07/22/2019
- Anti-hyperalgesic and anti-inflammatory effects of Citral (cas 5392-40-5) with β-cyclodextrin and hydroxypropyl-β-cyclodextrin inclusion complexes in animal models07/20/2019
- Preparation and characterization of Citral (cas 5392-40-5)-loaded solid lipid nanoparticles07/21/2019
- In vitro DNA binding studies of therapeutic and prophylactic drug Citral (cas 5392-40-5)07/19/2019
- Anti-inflammatory and anti-cancer activity of Citral (cas 5392-40-5): Optimization of Citral (cas 5392-40-5)-loaded solid lipid nanoparticles (SLN) using experimental factorial design and LUMiSizer®07/18/2019
- Physiological response of Saccharomyces cerevisiae to Citral (cas 5392-40-5) combined with thermal treatment07/17/2019
- Effect of drying and interfacial membrane composition on the antimicrobial activity of emulsified Citral (cas 5392-40-5)07/15/2019